| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
( Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut)
A review has been presented of selected aspects of 5-iododeoxyuridine (IUDR) and of 6-azauridine. Some of the basic problems which may be of pertinence to the successful use of IUDR clinically have been indicated. Although the role of IUDR as a chemotherapeutic agent in the treatment of neoplasms, either alone or in combination with other compounds or radiation, is still under investigation, its role as an anti-viral agent in the treatment of some established DNA-viral infections in animals as well as in man has been well substantiated.
* This investigation was supported by a grant (CY-5262) from the National Cancer Institute, U.S. Public Health Service.
This article has been cited by other articles:
![]() |
J. B. Rose and I. R. Coe Physiology of Nucleoside Transporters: Back to the Future. . . . Physiology, February 1, 2008; 23(1): 41 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Dewey, B. A. Sedita, and R. M. Humphrey Radiosensitization of X Chromosome of Chinese Hamster Cells Related to Incorporation of 5-Bromodeoxyuridine Science, April 22, 1966; 152(3721): 519 - 521. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |